199 related articles for article (PubMed ID: 29603014)
1. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer.
Byrne JD; Jajja MRN; O'Neill AT; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Cancer Chemother Pharmacol; 2018 Jun; 81(6):991-998. PubMed ID: 29603014
[TBL] [Abstract][Full Text] [Related]
2. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
Byrne JD; Jajja MR; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2200-5. PubMed ID: 26858448
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
4. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy.
Erstad DJ; Sojoodi M; Taylor MS; Ghoshal S; Razavi AA; Graham-O'Regan KA; Bardeesy N; Ferrone CR; Lanuti M; Caravan P; Tanabe KK; Fuchs BC
Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29903803
[TBL] [Abstract][Full Text] [Related]
5. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
Shirasu H; Todaka A; Omae K; Fujii H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Kobayashi M; Fukutomi A
Cancer Sci; 2019 Feb; 110(2):707-716. PubMed ID: 30447099
[TBL] [Abstract][Full Text] [Related]
6. Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis.
Bozkurt Duman B; Çil T
J Oncol Pharm Pract; 2020 Oct; 26(7):1738-1742. PubMed ID: 32070199
[TBL] [Abstract][Full Text] [Related]
7. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.
Todaka A; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Nakamori S; Yachi Y; Henmi T; Kobayashi M; Boku N; Mori K; Fukutomi A
Pancreas; 2018; 47(5):631-636. PubMed ID: 29683973
[TBL] [Abstract][Full Text] [Related]
8. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
Guion-Dusserre JF; Bertaut A; Ghiringhelli F; Vincent J; Quipourt V; Marilier S; Tharin Z; Bengrine-Lefevre L
World J Gastroenterol; 2016 Nov; 22(42):9378-9386. PubMed ID: 27895425
[TBL] [Abstract][Full Text] [Related]
9. A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction.
Gao J; Logan KA; Nesbitt H; Callan B; McKaig T; Taylor M; Love M; McHale AP; Griffith DM; Callan JF
J Control Release; 2021 Oct; 338():358-366. PubMed ID: 34481018
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer.
Xu X; Wu Q; Wang Z; Zheng S; Ge K; Jia C
Clin Exp Med; 2019 Feb; 19(1):149-157. PubMed ID: 30498929
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
Usón Junior PLS; Rother ET; Maluf FC; Bugano DDG
Clin Colorectal Cancer; 2018 Sep; 17(3):187-197. PubMed ID: 29615310
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery.
Zhan Q; Shen B; Deng X; Chen H; Jin J; Zhang X; Peng C; Li H
Int J Nanomedicine; 2013; 8():2465-72. PubMed ID: 23885173
[TBL] [Abstract][Full Text] [Related]
13. Updates in pancreatic cancer: Modest gains and hopeful targets.
Draper A
J Oncol Pharm Pract; 2019 Jan; 25(1):101-109. PubMed ID: 29580162
[TBL] [Abstract][Full Text] [Related]
14. [FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].
Ishigame T; Kimura T; Tsukida S; Suzushino S; Muto M; Sato N; Kofunato Y; Okada R; Kenjo A; Shimura T; Marubashi S
Gan To Kagaku Ryoho; 2019 Apr; 46(4):754-756. PubMed ID: 31164525
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters.
Deyme L; Barbolosi D; Gattacceca F
Cancer Chemother Pharmacol; 2019 Jan; 83(1):27-42. PubMed ID: 30446786
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study.
Qi F; Zheng Z; Yan Q; Liu J; Chen Y; Zhang G
Med Sci Monit; 2018 Apr; 24():1970-1979. PubMed ID: 29614063
[TBL] [Abstract][Full Text] [Related]
19. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
Caparello C; Meijer LL; Garajova I; Falcone A; Le Large TY; Funel N; Kazemier G; Peters GJ; Vasile E; Giovannetti E
World J Gastroenterol; 2016 Aug; 22(31):6987-7005. PubMed ID: 27610011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
